Chicago

Running trials

• Active, not recruiting

  An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

  NCT02808780· Source

• Active, not recruiting

  Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

  NCT02609776· Phase 1· Source

• Active, not recruiting

  A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

  NCT02489318· Phase 3· Source

• Active, not recruiting

  Infusion of Apomorphine: Long-term Safety Study

  NCT02339064· Phase 3· Source

• Active, not recruiting

  Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

  NCT02633943· Phase 3· Source

• Active, not recruiting

  A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204· Phase 3· Source

• Active, not recruiting

  A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Phase 3· Source

• Recruiting

  Product Surveillance Registry

  NCT01524276· Source

• Active, not recruiting

  Psoriasis Longitudinal Assessment and Registry

  NCT00508547· Source

• Active, not recruiting

  A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  NCT00606346· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

  NCT02252172· Phase 3· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

  NCT02140554· Phase 1/2· Source

• Completed

  A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

  NCT02195479· Phase 3· Source

• Completed

  A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT02076009· Phase 3· Source

• Completed

  A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

  NCT01998971· Phase 1· Source

• Completed

  A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT01776840· Phase 3· Source

• Completed

  A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

  NCT01712490· Phase 3· Source